权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Viral and host predictors of BK polyomavirus associated hemorrhagic cystitis

BK 多瘤病毒相关出血性膀胱炎的病毒和宿主预测因子

基本信息

批准号：
10203959
负责人：
JASON T BLACKARD
金额：
$ 67.47万
依托单位：
CHILDREN'S HOSP OF PHILADELPHIA
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-07-01 至 2025-06-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10203959
关键词：
Age Allogenic Antiviral Agents Antiviral Therapy Award BK Virus Bladder Bladder Injury Blood Transfusion Blood specimen Bone Marrow Transplantation Case-Control Studies Cell Therapy Chemotherapy-Oncologic Procedure Child Childhood Clinical Clinical Data Clinical Treatment Clinical Trials Combination Drug Therapy Complication Cox Models Cystitis Data Disease Engraftment Enrollment Evaluation Foundations Future Gender Gene Deletion Genes Genetic Polymorphism Genetic Variation Genome Glycoproteins Goals HIV/HCV Hemorrhage Hospital Costs Hospitalization Immune response Incidence Individual Infection Infusion procedures Injury Inpatients Knowledge Lead Length Length of Stay Medical center Membrane Modeling Molecular Morbidity - disease rate Mutation Obstruction Outcome Pain Participant Patient-Focused Outcomes Patients Pediatric Hospitals Persons Philadelphia Polyomavirus Infections Population Prevention strategy Procedures Proteins Proteomics Questionnaires RNA ROC Curve Research Research Project Grants Resolution Risk Sample Size Sampling Sensitivity and Specificity Supportive care T-Lymphocyte Testing Time Transfusion Transplant Recipients Urination Urine Validation Variant Vesicle Viral Viral Physiology Virulence Virus base chemotherapy cohort conditioning cost exosome graft vs host disease hematopoietic cell transplantation high risk immune reconstitution improved mortality mortality risk neutrophil next generation sequencing novel novel therapeutics patient oriented predictive modeling prevent prospective response targeted treatment transcriptome sequencing transcriptomics treatment strategy urinary urinary tract obstruction virus genetics young adult

项目摘要

PROJECT SUMMARY/ABSTRACT The overall goals of this proposal are to investigate the mechanisms of bladder injury (hemorrhagic cystitis) associated with BK polyomavirus (BKPyV) infection in children and young adults undergoing bone marrow transplantation (allogeneic hematopoietic cell transplantation, HSCT). BKPyV-associated hemorrhagic cystitis is a complication for up to 25% of allogeneic HSCT recipients. Hemorrhagic cystitis leads to patient morbidity from painful urination, prolonged hospitalizations, increased blood transfusion requirements, and invasive procedures when urinary obstruction is present. Each episode of hemorrhagic cystitis accounts for 10 additional hospital days and costs $70,000. In its most severe presentation, hemorrhagic cystitis may be associated with a higher risk of death. BKPyV replication in the urine can be detected in 80% of HSCT recipients, but not all of these patients will develop hemorrhagic cystitis. There are no antiviral therapies with proven efficacy against BKPyV and current treatment strategies for hemorrhagic cystitis are limited to supportive care. A major barrier to developing and testing novel therapies is our lack of understanding the mechanisms of bladder injury in patients with BKPyV replication. This also prevents the identification of the patients at highest risk for bladder injury. The central hypothesis of this proposal is that the risk of hemorrhagic cystitis after HSCT is a function of both BKPyV subtype and the host response to the virus. To test our hypothesis, we will study two separate prospective observational cohorts: an existing group of 193 children and young adults who received an allogeneic HSCT at Cincinnati Children’s Hospital Medical Center or the Children’s Hospital of Philadelphia with already banked urine samples and an independent validation cohort of 200 children and young adults undergoing allogeneic HSCT to be enrolled during the award period at these same two centers. The project’s specific aims are: 1) to test whether the population or within-person BKPyV diversity is different between patients with and without hemorrhagic cystitis after HSCT and to enroll the validation cohort; and 2) to test whether host cellular responses or specific gene polymorphisms are different between subjects with and without hemorrhagic cystitis after HSCT using proteomics and transcriptomics approaches. This study’s results are expected to increase our understanding of the viral and host mechanisms of bladder injury after HSCT. The data from this application are critical for identifying the patients at highest risk of hemorrhagic cystitis who would benefit from cellular therapies and other targeted, future prevention or treatment strategies.

项目总结/文摘